ICU ICU
Company Profile ↓Company Overview
ICU (ICU) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $1.23M (+814.1% YoY); net profit $-12.15M.
- Trailing 12 Months Year-on-year growth — revenue +814.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 814.07% |
Stock Price Performance
| 1 Year: | -56.67% |
| 6 Months: | +23.27% |
| 3 Months: | -31.67% |
| 1 Month: | -40.43% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)31.29 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 75.7% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 68.00K | 293.00K | 338.00K | 183.00K | 495.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 68.00K | 293.00K | 311.00K | 169.00K | 449.00K |
| Operating Income | -5.24K | -125.96K | -209.72K | -411.40K | -812.00K | -1.31M | -1.77M | -4.58M | -3.75M | -2.94M | -3.95M | -4.67M | -4.46M | -3.82M | -1.76M | -3.58M | -3.60M |
| Net Income | - | 1.71M | -1.98M | 235.98K | -1.00M | -902.00K | -1.89M | -7.10M | -2.45M | -7.23M | -12.70M | -3.24M | -4.48M | -3.77M | -2.00M | -3.47M | -3.52M |
| Diluted EPS | - | 0.18 | - | - | -0.14 | -0.12 | -0.26 | -0.54 | -4.10 | -9.02 | -4.73 | -1.03 | -1.10 | -0.44 | -0.18 | - | - |
| R&D Expense | - | - | - | - | 355.00K | 596.00K | 727.00K | 1.73M | 1.98M | 1.09M | 1.70M | 2.33M | 2.34M | 2.43M | 1.04M | 1.85M | 2.34M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | - | 0 | 135.00K | 1.23M |
| Gross Profit | - | - | 0 | 135.00K | 1.18M |
| Operating Income | -4.45M | -11.61M | -14.21M | -17.84M | -12.18M |
| Net Income | -4.60M | -12.19M | -26.23M | -24.83M | -12.15M |
| Diluted EPS | -0.63 | -1.48 | -30.26 | -6.63 | - |
| R&D Expense | 2.77M | 2.50M | 5.97M | 9.11M | 7.52M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 269.21K | 603.00K | 3.04M | 3.65M | 2.60M | 2.51M | 3.51M | 4.66M | 14.16M |
| Total Equity | 1.77M | -2.82M | -20.76M | -23.38M | -11.76M | -16.02M | -13.87M | -2.18M | 10.42M |
| Cash & Equivalents | 38.39K | 51.57K | - | - | - | - | - | - | - |
| Long Term Debt | - | - | 7.65M | - | - | - | 4.14M | - | - |
| Total Liabilities | 249.44K | 3.42M | 23.80M | 27.02M | 14.35M | 18.52M | 17.38M | 6.84M | 3.74M |
| Current Liabilities | 249.44K | 3.12M | 16.15M | 21.28M | 14.35M | 12.80M | 13.05M | 6.84M | 3.74M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -5.11M | -7.79M | -10.29M | -16.01M | -13.60M |
| Investing Cash Flow | -105.57M | - | - | - | - |
| Financing Cash Flow | 2.82M | 7.33M | 10.41M | 17.65M | 23.76M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 100.0% | 95.7% |
| Operating Margin % | - | - | - | -13,216.3% | -986.6% |
| Net Margin % | - | - | - | -18,392.6% | -984.6% |
| ROE % | 163.2% | 58.7% | 189.1% | 1,137.4% | -116.6% |
| ROCE % | 176.8% | 88.6% | 149.1% | 817.3% | -116.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ICU
ICU Medical (ICUI) Reports Q2: Everything You Need To Know Ahead Of Earnings - StockStory
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQOUJ6SzdxU2hBNkg3My1jM2x0NHBGdjBHbE9aVko3UFF4S1dHd3N5UEN2RGdiQ1dxdGJBRkZhbDVHQTdTOUpiWkJuY3pxdVVGS0x2dWtSN0lrc0w5ZjRRd1NvVGZoY3MybGdzSHFsY2dqU2RBQ3ViaHJjZzRvZ25wNTNWZ0dTeWFOU1FHaW…
ICU Medical (ICUI) Could Be 2% Undervalued As Recall Questions Meet A Full P E - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxOTll4YUxIWS1vdWx6VkxFUFRVSGJPeWI0X3pMN2ZYNkxfeEVrZ2NJQy1rU2MzdUg2QW5yZWpoRTN4eUQwQXJaaHo1Vm4wd19JeXlkWVRTeFpJNmVwelMwQzhwSkhYU2xwU1hYNmJTVnJ2NEpSOGhBMjQ1eVpkWnJnMEswUTdVa3A4S1NVdD…
ICU Medical, Inc. (ICUI) Stock Analysis: Assessing Growth Potential And Analyst Consensus - DirectorsTalk Interviews
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxNYlVtTjZDeDExN1dnUFRHbVhxOFR6VUl2R1pvNDloOVlGSTZsUGpnbU50Rmh2QU1ZcDFtcTFKdnlvbnFzcENDVDdOdHBDcXdEMU12RU1NdlZGZHlfcElZZmdaZVFiWjk3VTdvUmh3QVpYRUxxUDBUNzFWNjIxNThsU2J0YnBXemV0XzhqRn…
ICU Medical (ICUI) Stock Valuation Check After Recent Momentum And Discount To Estimated Fair Value - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQeDZjdVU3Ulh0dHViWVpRdk1OdnpFSlhkZjZwMTdSeUdBdVBYSWN0ZGFEZHFEaVk4UmsybW1uRklVZmtoZ19UMFhsLUZvZTVyWUlVbDZwNmFBT1N2UExGMkVnZ0pCNVFtMlZBZ3M5SGc2UDY4Qm9DYnpoUHdJeThScTVlUnY5Q05PdGdsXz…
SeaStar Medical CEO to present at virtual investor summit June 24 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPYm1nbnBBdGxEcjYtWGxCM3hYVGdnWTJRd1IyNDRfdFhXYWJaeFBTUjhPTnAyOGY3VjR5Ymh0bzNMMGUxMFV5TUFGT3hWRk9aTDhSRjJJWlI0ZFdpV1RFcFBNT1Z5ZGxOVjBBZ2h6SGhNazMtQWxENzlJeWNsa2NwMjdmRk9nX2VSVlY2dj…
KeyBanc raises ICU Medical stock price target on pump growth - Investing.com
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxObE5HTENKY0JQN2Y2V3FSWnVLbER3V3h4clREWFBzZEhNSExtNE9KYllqa1pkOXM3UDYycGZxb2hrV05ucG50SlRCcW1IakpyTjNObFVia3R4YVVtUHd2VnpwY25FTVRnaTdnSG5EWHEzbmgyaS1aMWJYclVNbXB3YWNsb0FPZzhhVlA0b2…
ICU — Frequently Asked Questions
What is the current share price of ICU?
As of 2026-08-05 17:25 PDT, ICU trades at $3.02 on NASDAQ/NYSE. Its 52-week range is $2.21 to $12.40.
What is the P/E ratio of ICU?
ICU trades at a trailing price-to-earnings (P/E) ratio of -0.46.
What is the return on equity (ROE) of ICU?
ICU has a return on equity (ROE) of -116.65%. Its return on capital employed (ROCE) is -116.89%.
Is ICU a good stock to buy?
This page provides a data-driven analysis of ICU, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.